Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti T-lymphocyte globulin - Neovii Biotech

Drug Profile

Anti T-lymphocyte globulin - Neovii Biotech

Alternative Names: Anti-T-lymphocyte immune globulin; Antithymocyte globulin - Fresenius; Antithymocyte immunoglobulin (rabbit) - Neovii Biotech; ATG S Fresenius; ATG-Fresenius-S; ENZN-2053; EZ-2053; Grafalon; US-ATG-F

Latest Information Update: 15 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fresenius Biotech
  • Developer Neovii Biotech
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection; Transplant rejection
  • Discontinued Lung transplant rejection

Most Recent Events

  • 15 Feb 2019 Anti T lymphocyte golubulin is not yet available for Graft-versus-host disease (Prevention) in Croatia, Cyprus, Estonia, France, Ireland, Italy, Latvia, Lithuania, Poland, Romania, Slovakia and Slovenia
  • 15 Feb 2019 No development reported - Phase-III for Graft-versus-host disease (Prevention) in Australia (IV)
  • 05 Jul 2018 Anti T-lymphocyte globulin licensed to Mundipharma in China and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top